Pulmonary nocardiosis in cystic fibrosis

Shannon T. Thorn, Mark A Brown, James J. Yanes, Duane L Sherrill, Juliana Pugmire, K. Arbor Anderson, Stephen A Klotz

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: The treatment of Nocardia species found in the sputum of cystic fibrosis patients is of unknown value. Methods: We conducted a retrospective analysis of the impact of directed oral antibiotic therapy against Nocardia spp. isolated from the sputum of 17 cystic fibrosis patients over a 10-year period. Pulmonary Function Tests were used as the clinical indicator of the disease state and the data were analyzed by general linear mixed model statistics with univariate analysis. Results: Pulmonary Function Test values of all patients studied showed no significant difference before, during, or after the antibiotic treatment period. Treatment groups did not differ from non-treatment groups. This held true for Forced Expiratory Volume over 1 s and Functional Vital Capacity analysis. In addition, individual patient analysis did not reveal any trends or outliers. Conclusions: Oral antibiotic therapy of cystic fibrosis patients colonized with Nocardia does not appear to affect clinical outcome. This suggests that deferring therapy may be an acceptable alternative and justifies conducting a future placebo controlled trial. In addition, this study model may be useful in analyzing the effect of therapy on other rare and difficult organisms, such as fungi and mycobacteria in the cystic fibrosis population.

Original languageEnglish (US)
Pages (from-to)316-320
Number of pages5
JournalJournal of Cystic Fibrosis
Volume8
Issue number5
DOIs
StatePublished - Sep 2009

Fingerprint

Nocardia Infections
Cystic Fibrosis
Nocardia
Respiratory Function Tests
Anti-Bacterial Agents
Sputum
Therapeutics
Vital Capacity
Forced Expiratory Volume
Mycobacterium
Linear Models
Fungi
Placebos

Keywords

  • Cystic fibrosis
  • General linear mixed model statistics
  • Nocardiosis
  • Pulmonary function tests
  • Pulmonary nocardiosis
  • Treatment of nocardiosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pediatrics, Perinatology, and Child Health

Cite this

Pulmonary nocardiosis in cystic fibrosis. / Thorn, Shannon T.; Brown, Mark A; Yanes, James J.; Sherrill, Duane L; Pugmire, Juliana; Anderson, K. Arbor; Klotz, Stephen A.

In: Journal of Cystic Fibrosis, Vol. 8, No. 5, 09.2009, p. 316-320.

Research output: Contribution to journalArticle

Thorn, Shannon T. ; Brown, Mark A ; Yanes, James J. ; Sherrill, Duane L ; Pugmire, Juliana ; Anderson, K. Arbor ; Klotz, Stephen A. / Pulmonary nocardiosis in cystic fibrosis. In: Journal of Cystic Fibrosis. 2009 ; Vol. 8, No. 5. pp. 316-320.
@article{23966c7d3d234df8ba2db0a456226832,
title = "Pulmonary nocardiosis in cystic fibrosis",
abstract = "Background: The treatment of Nocardia species found in the sputum of cystic fibrosis patients is of unknown value. Methods: We conducted a retrospective analysis of the impact of directed oral antibiotic therapy against Nocardia spp. isolated from the sputum of 17 cystic fibrosis patients over a 10-year period. Pulmonary Function Tests were used as the clinical indicator of the disease state and the data were analyzed by general linear mixed model statistics with univariate analysis. Results: Pulmonary Function Test values of all patients studied showed no significant difference before, during, or after the antibiotic treatment period. Treatment groups did not differ from non-treatment groups. This held true for Forced Expiratory Volume over 1 s and Functional Vital Capacity analysis. In addition, individual patient analysis did not reveal any trends or outliers. Conclusions: Oral antibiotic therapy of cystic fibrosis patients colonized with Nocardia does not appear to affect clinical outcome. This suggests that deferring therapy may be an acceptable alternative and justifies conducting a future placebo controlled trial. In addition, this study model may be useful in analyzing the effect of therapy on other rare and difficult organisms, such as fungi and mycobacteria in the cystic fibrosis population.",
keywords = "Cystic fibrosis, General linear mixed model statistics, Nocardiosis, Pulmonary function tests, Pulmonary nocardiosis, Treatment of nocardiosis",
author = "Thorn, {Shannon T.} and Brown, {Mark A} and Yanes, {James J.} and Sherrill, {Duane L} and Juliana Pugmire and Anderson, {K. Arbor} and Klotz, {Stephen A}",
year = "2009",
month = "9",
doi = "10.1016/j.jcf.2009.07.005",
language = "English (US)",
volume = "8",
pages = "316--320",
journal = "Journal of Cystic Fibrosis",
issn = "1569-1993",
publisher = "Elsevier",
number = "5",

}

TY - JOUR

T1 - Pulmonary nocardiosis in cystic fibrosis

AU - Thorn, Shannon T.

AU - Brown, Mark A

AU - Yanes, James J.

AU - Sherrill, Duane L

AU - Pugmire, Juliana

AU - Anderson, K. Arbor

AU - Klotz, Stephen A

PY - 2009/9

Y1 - 2009/9

N2 - Background: The treatment of Nocardia species found in the sputum of cystic fibrosis patients is of unknown value. Methods: We conducted a retrospective analysis of the impact of directed oral antibiotic therapy against Nocardia spp. isolated from the sputum of 17 cystic fibrosis patients over a 10-year period. Pulmonary Function Tests were used as the clinical indicator of the disease state and the data were analyzed by general linear mixed model statistics with univariate analysis. Results: Pulmonary Function Test values of all patients studied showed no significant difference before, during, or after the antibiotic treatment period. Treatment groups did not differ from non-treatment groups. This held true for Forced Expiratory Volume over 1 s and Functional Vital Capacity analysis. In addition, individual patient analysis did not reveal any trends or outliers. Conclusions: Oral antibiotic therapy of cystic fibrosis patients colonized with Nocardia does not appear to affect clinical outcome. This suggests that deferring therapy may be an acceptable alternative and justifies conducting a future placebo controlled trial. In addition, this study model may be useful in analyzing the effect of therapy on other rare and difficult organisms, such as fungi and mycobacteria in the cystic fibrosis population.

AB - Background: The treatment of Nocardia species found in the sputum of cystic fibrosis patients is of unknown value. Methods: We conducted a retrospective analysis of the impact of directed oral antibiotic therapy against Nocardia spp. isolated from the sputum of 17 cystic fibrosis patients over a 10-year period. Pulmonary Function Tests were used as the clinical indicator of the disease state and the data were analyzed by general linear mixed model statistics with univariate analysis. Results: Pulmonary Function Test values of all patients studied showed no significant difference before, during, or after the antibiotic treatment period. Treatment groups did not differ from non-treatment groups. This held true for Forced Expiratory Volume over 1 s and Functional Vital Capacity analysis. In addition, individual patient analysis did not reveal any trends or outliers. Conclusions: Oral antibiotic therapy of cystic fibrosis patients colonized with Nocardia does not appear to affect clinical outcome. This suggests that deferring therapy may be an acceptable alternative and justifies conducting a future placebo controlled trial. In addition, this study model may be useful in analyzing the effect of therapy on other rare and difficult organisms, such as fungi and mycobacteria in the cystic fibrosis population.

KW - Cystic fibrosis

KW - General linear mixed model statistics

KW - Nocardiosis

KW - Pulmonary function tests

KW - Pulmonary nocardiosis

KW - Treatment of nocardiosis

UR - http://www.scopus.com/inward/record.url?scp=69549084425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69549084425&partnerID=8YFLogxK

U2 - 10.1016/j.jcf.2009.07.005

DO - 10.1016/j.jcf.2009.07.005

M3 - Article

VL - 8

SP - 316

EP - 320

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

SN - 1569-1993

IS - 5

ER -